Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Aegerion (AEGR) PT Lowered to $70 at Deutsche Bank Due to Slow Patient Growth
May 7, 2014 8:37 AM EDTDeutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) an reduced its price target to $70.00 (from $115.00). Analyst Robyn Karnauskas expressed caution due to slow patient growth.
"Juxtapid 1Q revenues at $27M were lower than consensus at $33.6M primarily due to lower sales in ex-US.... More
Cowen Downgrades Aegerion Pharmaceuticals (AEGR) to Market Perform
May 7, 2014 7:27 AM EDTCowen downgraded Aegerion Pharmaceuticals (NASDAQ: AEGR) from Outperform to Market Perform with a price target of $36.00 (from $85).
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $44.16 yesterday.
... MoreAegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 10c
May 6, 2014 4:34 PM EDTAegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q1 EPS of ($0.25), $0.10 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $27 million versus the consensus estimate of $33.58 million.
Highlights
Aegerion achieved $27.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the first-quarter of 2014. 96% of net product sales in the first quarter were from the United States business, representing growth of 24% over net product sales from the U.S. business in the prior quarter. The Company now expects to achieve between $180 million and $200 million of net product sales... More